Download PDF
Thromb Haemost 1989; 61(03): 409-414
DOI: 10.1055/s-0038-1646605
Original Article
Schattauer GmbH Stuttgart

Immunoreactivity of Tissue Plasminogen Activator and of Its Inhibitor Complexes

Biochemical and Multicenter Validation of a Two Site Immunosorbent Assay
M Rånby
Biopool A B, Ume7å, Sweden
,
G Nguyen
1   The Haematology Laboratory, Hôpital Hôtel Dieu, Paris, France
,
P Y Scarabin
2   The Inserm U 258, Paris, France
,
M Samama
1   The Haematology Laboratory, Hôpital Hôtel Dieu, Paris, France
› Author Affiliations
Further Information

Publication History

Received 30 June 1988

Accepted after revision 02 February 1989

Publication Date:
24 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

An enzyme linked immunosorbent assay (ELISA) based on goat polyclonal antibodies against human tissue plasminogen activator (tPA) was evaluated. The relative immunoreactivity of tPA in free form and tPA in complex with inhibitors was estimated by ELISA and found to be 100, 74, 94, 92 and 8l% for free tPA and tPA in complex with PAI-1, PAI-2, α2-antiplasmin and C1-inhibitor, respectively. Addition of tPA to PAI-1 rich plasma resulted in rapid and total loss of tPA activity without detectable loss of ELISA response, indicating an immunoreactivity of tPA in tPA/PAI-1 complex of about l00%. Three different treatments of citrated plasma samples (acidification/reneutralization, addition of 5 mM EDTA or of 0.5 M lysine) prior to determination by ELISA all resulted in increased tPA levels. The fact that the increase was equally large in all three cases along with good analytical recovery of tPA added to plasffi, supported the notion that all tPA antigen present in plasma samples is measured by the ELISA. Analysis by ELISA of fractions obtained by gel filtration of plasma from a patient undergoing tPA treatment identified tPA/inhibitor complexes and free tPA but no low molecular weight degradation products of tPA. Determinations of tPA antigen were made at seven French clinical laboratories on coded and randomized plasma samples with known tPA antigen content. For undiluted samples there was no significant difference between the tPA levels found and those known to be present. The between-assay coefficient of variation was 7 to 10%. In conclusion, the ELISA appeared suited for determination of total tPA antigen in human plasma samples.

Keywords

Tissue plasminogen activator - tPA - Immunoreactivity - Immunological determination - Elisa - Multicenter validation
 

  • References

  • 1 Isacsson S, Nilsson IM. Defective fibrinolysis in blood and vessel walls in recurrent “idopathic” venous thrombosis. Acta Chir Scand 1972; 138: 313-319
    PubMedGoogle Scholar
  • 2 Aoki N. Physiological endogenous fibrinolysis: Its congenital abnormalities. In: Progress in Fibrinolysis Vol6. Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. (eds) Churchill Livingstone; Edinburgh: 1983. pp 3-12
    Google Scholar
  • 3 Booth NA, Bennett B, Wijngaards G, Grieve JH K. A new life long hemorrhagic disorder due to excess plasminogen activator. Blood 1983; 61: 267-275
    PubMedGoogle Scholar
  • 4 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
    CrossrefPubMedGoogle Scholar
  • 5 Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-661
    PubMedGoogle Scholar
  • 6 Nilsson T, Wallén P, Mellbring G. In vivo metabolism of human tissue type plasminogen activator. Scand J Haematol 1984; 33: 49-53
    PubMedGoogle Scholar
  • 7 Wiman B, Chmielewska J, Rånby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor JBC. 1984; 259: 3644-3647
    PubMedGoogle Scholar
  • 8 Kruithof EK O, Tran-Thang C, Ransijn A. Bachmann E Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
    PubMedGoogle Scholar
  • 9 Wiman B, Mellbring G, Rånby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific method. Clin Chim Acta 1983; 127: 279-288
    CrossrefPubMedGoogle Scholar
  • 10 Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 1987; 57: 67-72
    PubMedGoogle Scholar
  • 11 Holmberg L, Kristoffersen A, Lecander I, Wallén P, Åstedt B. Immunoradiometric quantification of tissue plasminogen activator and urokinase in plasma after various stimuli. Haemostasis 1982; 11 suppl (Suppl. 01) 31
    PubMedGoogle Scholar
  • 12 Bergsdorf N, Nilsson T, Wallen P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemostas 1983; 50: 740-744
    PubMedGoogle Scholar
  • 13 Rijken DC, Juhan-Vague I, DeCock F, Collen D. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. J Lab Clin Med 1983; 101: 274-284
    PubMedGoogle Scholar
  • 14 Juhan-Vague I, Rijken DC, De Cock F, Mendez C, Collen D. Extrinsic plasminogen activitor levels in clinical plasma samples. In: Progress in Fibrinolysis Vol6. Davidson JF, Bachman F, Bouvier CA, Kruithof EK O. (eds) Churchill Livingstone; Edinburgh: 1983. pp 65-69
    Google Scholar
  • 15 Urdén G, Blombäck M. Determination of tissue plasminogen activator in plasma samples by means of a radioimmune assay. Scand J Clin Invest 1984; 44: 495-502
    CrossrefPubMedGoogle Scholar
  • 16 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687
    PubMedGoogle Scholar
  • 17 Korninger C, Speiser W, Wojta J, Binder BR. Sandwich ELISA for t-PA antigen employing a monoclonal antibody. Thromb Res 1986; 41: 527-535
    CrossrefPubMedGoogle Scholar
  • 18 Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentration in plasma as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160-2165
    PubMedGoogle Scholar
  • 19 Wun TC, Capuano A. Immunoradiometric quantitation of tissue plasminogen activator related antigen in human plasma crypticity phenomenon and relationship to plasma fibrinolysis. Blood 1987; 69: 1348-1353
    PubMedGoogle Scholar
  • 20 Wallén P, Bergsdorf N, Rånby M. Purification and identification of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin. Biochim Biophys Acta 1982; 719: 318-328
    CrossrefPubMedGoogle Scholar
  • 21 Wallén P, Pohl G, Bergsdorf N, Rånby M, Ny T, Jömvall H. Purification and characterization of a melanoma cell plasminogen activator. Eur J Biochem 1983; 132: 681-686
    CrossrefPubMedGoogle Scholar
  • 22 Brändström A, Ranby M. t-PA protein determination: Improved accuracy through composition conscious amino acid analysis (CC-AAA). Thromb Haemostas 1987; 58: 437 (Abstr 1609)
    PubMedGoogle Scholar
  • 23 Lecander I, Roblin R, Astedt B. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. Br J Haematol 1984; 57: 407-412
    CrossrefPubMedGoogle Scholar
  • 24 Verstraete M, Bleifeld W, Brower RW. et al Double blind randomized trial of intravenous tissue type plasminogen activator in acute myocardial infarction. Lancet 1985; 8433: 842
    PubMedGoogle Scholar
  • 25 Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
    CrossrefPubMedGoogle Scholar
  • 26 Devries SR, Fox KA A, Robinson A, Rodriguez U, Sobel BE. Determinants of clearance of tissue-type plasminogen activator (t-PA) from the circulation. Fibrinolysis 1987; 1: 17-21
    PubMedGoogle Scholar